Abstract: Embodiments of the present invention provide for a core stage in an application-specific integrated circuit core which drives both a clock pulse signal and a clock pulse negative/complement signal concurrently, thereby resulting in perfectly aligned signals. The core stage can include a pulse generator, a clock distribution circuit, and a set of latches.

Abstract: Embodiments of the present invention provide for a core stage in an application-specific integrated circuit core which drives both a clock pulse signal and a clock pulse negative/complement signal concurrently, thereby resulting in perfectly aligned signals. The core stage can include a pulse generator, a clock distribution circuit, and a set of latches.

Abstract: Embodiments of the invention provide for a dynamic pulse generator which can combine both the sequential element and the pulse logic into one stage, thereby eliminating the wasted time resulting from a pulse generator' input-to-output propagation delay. The dynamic pulse generator can include a plurality of P-MOS an N-MOS transistors, a first delay element, and a second delay element.

Abstract: Embodiments of the invention provide for integrated circuits for testing one or more transistors for process variation effects. According to an embodiment, the integrated circuit can include: a plurality of ring oscillator macro circuits, wherein each ring oscillator macro circuit includes two ring oscillators, a first multiplexer, and a first divide-by-two circuit; a multiplexer stage; a divide-by-two circuit stage; a second multiplexer; a second divide-by-two circuit; and frequency measurement circuit. According to another embodiment, the integrated circuit can include: a first shift register including a plurality of devices-under-test; a second shift register including a plurality of static latches; a first multiplexer configured to receive outputs from each of the plurality of DUTs; a second multiplexer configured to receive outputs from each of the plurality of static latches; and a comparator configured to compare an output from the first multiplexer with an output from the second multiplexer.

Abstract: Power dissipation of sequential static latch, implemented in CMOS, may be reduced by removing clocked elements from the circuit. One way to do this may be to replace a clocked digital feedback path with an analog programmable feedback path. An analog programmable feedback path, such as disclosed, may, for example, provide a constant, non-clocked bias by providing constant bias voltages to transistors in the feedback path such that they function as analog devices rather than digital switches. This bias may be adjusted, e.g., to reflect the circuit's operating environment.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: A method for validating a set of payload data by means of said servers. The method includes validating information related to a set of payload data, based on which a check code has been calculated and encrypted by means of an asymmetric cryptographic key pair (A). The encrypted check code (1.11) has been stored at the archive server and associated with a time stamp, which can be used for validation of the set of payload data. The method may enable a selective revocation of certificates that have been used for signing the set of payload data.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: A method for validating a set of payload data by means of said servers. The method includes validating information related to a set of payload data, based on which a check code has been calculated and encrypted by means of an asymmetric cryptographic key pair (A). The encrypted check code (1.11) has been stored at the archive server and associated with a time stamp, which can be used for validation of the set of payload data. The method may enable a selective revocation of certificates that have been used for signing the set of payload data.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: The present invention relates to a method and a device for ensuring information integrity and non-repudiation over time. At least one example embodiment provides a mechanism for secure distribution of information, which information relates to an instance in time when usage of cryptographic key pairs associated with a certain brand identity commenced, as well as when the key pairs ceased to be used, i.e. when the key pairs were revoked. The mechanism further allows a company or an organization to tie administration of cryptographic key pairs and a procedure for verifying information integrity and non-repudiation to their own brand. This can be seen as a complement or an alternative to using a certificate authority (CA) as a trusted third party, which CA guarantees an alleged relation between a public key and the identity of the company or organization using the cryptographic key pair to which that public key belongs.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides immediate release pharmaceutical compositions comprising a polyglycol having a molecular weight of from about 900 to about 17,000 daltons, a drug substance, one or more effervescent agents, and, optionally, one or more disintegrants, such that the composition is formulated to be resistant to abuse by intake of alcohol.